Successful salvage treatment for relapse after autologous stem cell transplantation in a patient with Hodgkin's disease--a case report.
We report a patient who relapsed 12 months after undergoing high-dose chemotherapy followed by autologous stem cell transplantation for refractory Hodgkin's disease, nodular sclerosis. The patient received sequential single-dose chemotherapy consisting of 140 mg/m2 epirubicin, 1.4 mg/m2 vincristine, and 50 mg/m2 prednisole on day 1, followed by 4000 mg/m2 cyclophosphamide on day 15 and 2000 mg/m2 etoposide on day 30. This regimen was given twice, predominantly on an outpatient basis without major toxicity. The patient reached a complete remission and has remained free of disease after an observation period of 48 months. Single-dose sequential treatment should be considered for refractory Hodgkin's disease, even for relapse after high-dose chemotherapy, as escalated single doses of cytostatic agents may overcome drug resistance.
Kaiser
U
U
Zentrum Innere Medizin, Abt. Hämatologie/Onkologie, Philipps Universität Marburg, Germany. kaiseru@mailer.uni-marburg.de
Weide
R
R
Wolf
M
M
D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000601:surgery; D006801:Humans; D012008:Recurrence; D016879:Salvage Therapy; D014182:Transplantation, Autologous; D016896:Treatment Outcome
D000970:Antineoplastic Agents